Georgala S, Gregoriou S, Georgala C, Papaioannou D, Befon A, Kalogeromitros D, Rigopoulos D
Department of Dermatology, A. Sygros Hospital, University of Athens, Athens, Greece.
Dermatology. 2007;215(3):209-12. doi: 10.1159/000106578.
Non-specific balanitis is a common inflammatory dermatosis with frequent relapses and considerable impact on male sexual life.
To evaluate the efficacy and safety of pimecrolimus 1% cream in recurrent non-specific balanitis.
Twenty-six patients with recurrent flares of non-specific balanitis were randomly assigned to 1 group applying pimecrolimus cream 1% and 1 group applying placebo on the glans twice daily for 7 days. The patients were assessed on day 14. They were instructed to continue applying the agent whenever symptoms initialized for the following 90 days and take account of the cumulative days with symptoms.
Seven out of the 11 (63.6%) patients in the pimecrolimus group and 1 out of 11 (9%) in the control group were free of all symptoms and lesions after 14 days, 3 (27.3%) in both groups reported improvement, while 1 (9.1%) in the pimecrolimus and 7 (63.6%) in the control group remained unaffected. (chi(2) = 9.0, d.f. = 2, p = 0.011). Days with symptoms during the 90-day follow-up period were 7.50 +/- 3.02 for the pimecrolimus and 17.62 +/- 4.40 for the control group (p = 0.000064).
Pimecrolimus 1% cream is promising in relieving symptoms and signs of non-specific balanitis during flares and controlling the disease during long-term follow-up.
非特异性龟头炎是一种常见的炎症性皮肤病，复发频繁，对男性性生活有相当大的影响。
评估1%吡美莫司乳膏治疗复发性非特异性龟头炎的疗效和安全性。
26例复发性非特异性龟头炎患者被随机分为两组，一组每天两次在龟头涂抹1%吡美莫司乳膏，另一组涂抹安慰剂，持续7天。在第14天对患者进行评估。他们被指示在接下来的90天内，每当症状出现时继续涂抹药物，并记录有症状的累计天数。
14天后，吡美莫司组11例患者中有7例（63.6%）所有症状和皮损消失，对照组11例中有1例（9%）；两组均有3例（27.3%）报告症状改善，而吡美莫司组有1例（9.1%）、对照组有7例（63.6%）未受影响。（χ² = 9.0，自由度 = 2，p = 0.011）。在90天随访期内，吡美莫司组有症状的天数为7.50±3.02天，对照组为17.62±4.40天（p = 0.000064）。
1%吡美莫司乳膏在缓解非特异性龟头炎发作时的症状和体征以及长期随访中控制疾病方面前景良好。
